3504-37-8

Basic information

• Product Name: N-CBZ-LEU-LEU METHYL ESTER
• Synonyms: N-CBZ-LEU-LEU METHYL ESTER;N-BENZYLOXYCARBONYL-L-LEUCYL-L-LEUCINE METHYL ESTER;Z-LEU-LEU-OME;Z-LEU-LEU METHYL ESTER;Z-LEUCYL-L-LEUCINE METHYL ESTER;N-carbobenzyloxy-Leu-Leu methyl ester;2-[[2-(benzyloxycarbonylamino)-4-methyl-pentanoyl]amino]-4-methyl-valeric acid methyl ester;methyl 4-methyl-2-[[4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoate
• CAS NO: 3504-37-8
• Molecular Formula: C₂₁H₃₂N₂O₅
• Molecular Weight: 392.49
• Product Categories: Dipeptides;Dipeptides and Tripeptides;Peptides
• Mol File: 3504-37-8.mol
• Article Data: 20

Chemical Properties

• Melting Point: 97-98 °C
• Boiling Point: 546.5°C at 760 mmHg
• Flash Point: 284.3°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 5.34E-12mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: −20°C
• PKA: 11.13±0.46(Predicted)
• CAS DataBase Reference: N-CBZ-LEU-LEU METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-CBZ-LEU-LEU METHYL ESTER(3504-37-8)
• EPA Substance Registry System: N-CBZ-LEU-LEU METHYL ESTER(3504-37-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 3504-37-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H32N2O5/c1-14(2)11-17(19(24)22-18(12-15(3)4)20(25)27-5)23-21(26)28-13-16-9-7-6-8-10-16/h6-10,14-15,17-18H,11-13H2,1-5H3,(H,22,24)(H,23,26)

Upstream product

• 2018-66-8 Z-Leu-OH 
• 83025-93-8 Benzyloxycarbonyl-L-leucin-phthalimidyl-⁽²⁾-ester 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 2666-93-5 (S)-Leu-OMe 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 4652-65-7 (S)-2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 
• 1738-87-0 Z-Leu-ONp 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 51021-87-5 N-benzyloxycarbonyl-L-leucine methyl ester 
• 501-53-1 benzyl chloroformate 
• 61-90-5 L-leucine 
• 125814-24-6 Z-Leu-NCA 
• 53363-87-4 N-(benzyloxycarbonyl)leucine dicyclohexylamine salt 
• 16257-39-9 O-(N-Z-L-Leu)-pivalohydroxamsaeure 

Downstream Products

• 18867-97-5 carbobenzoxy-L-leucyl-L-leucyl-L-leucine 
• 106561-18-6 N-(benzyloxycarbonyl)-L-leucyl-L-leucyl-L-leucine methyl ester 
• 98695-41-1 N-carbobenzoxy-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucine methyl ester 
• 133407-82-6 N-(benzyloxycarbonyl)-leucinylleucinylleucinal 

Relevant articles and documents

Application of proteasome inhibitor in inhibition of novel coronavirus

The invention provides application of a proteasome inhibitor in inhibition of a novel coronavirus or preparation of novel coronavirus inhibitors. The proteasome inhibitor has a structure represented by a formula (I) or isomers, pharmaceutically acceptable salts thereof and prodrugs thereof. According to the application, by applying the proteasome inhibitor to inhibition of the novel coronavirus, good inhibiting activity is obtained, and a novel treatment way of think is provided for diseases such as pneumonia caused by the novel coronavirus.

A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities

Inhibitors of the proteasome have been extensively studied for their applications in the treatment of human diseases such as hematologic malignancies, autoimmune disorders, and viral infections. Many of the proteasome inhibitors reported in the literature target the non-primed site of proteasome's substrate binding pocket. In this study, we designed, synthesized and characterized a series of novel α-keto phenylamide derivatives aimed at both the primed and non-primed sites of the proteasome. In these derivatives, different substituted phenyl groups at the head group targeting the primed site were incorporated in order to investigate their structure-activity relationship and optimize the potency of α-keto phenylamides. In addition, the biological effects of modifications at the cap moiety, P1, P2 and P3 side chain positions were explored. Many derivatives displayed highly potent biological activities in proteasome inhibition and anticancer activity against a panel of six cancer cell lines, which were further rationalized by molecular modeling analyses. Furthermore, a representative α-ketoamide derivative was tested and found to be active in inhibiting the cellular infection of SARS-CoV-2 which causes the COVID-19 pandemic. These results demonstrate that this new class of α-ketoamide derivatives are potent anticancer agents and provide experimental evidence of the anti-SARS-CoV-2 effect by one of them, thus suggesting a possible new lead to develop antiviral therapeutics for COVID-19.

Proline boric acid compound and preparation method and applications thereof

The invention provides a compound whose structure is shown as a formula (I) or a salt thereof. The compound is a proline boric acid proteasome inhibitor compound, and has good proteasome inhibitory activity and excellent druggability. The structural formula of the compound is shown as the formula (I).